AKER - Akers Biosciences, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
3.5600
+0.0400 (+1.14%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Triple Moving Average Crossover

Triple Moving Average Crossover

Performance Outlook
  • Short Term
    2W - 6W
  • Mid Term
    6W - 9M
  • Long Term
    9M+
Previous Close3.5200
Open3.5200
Bid3.5100 x 1400
Ask3.5600 x 800
Day's Range3.4800 - 3.5978
52 Week Range1.5500 - 16.3200
Volume402,959
Avg. Volume2,657,582
Market Cap21.795M
Beta (5Y Monthly)0.39
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Hedge Funds Are Nibbling On Akers Biosciences Inc (AKER)
    Insider Monkey

    Hedge Funds Are Nibbling On Akers Biosciences Inc (AKER)

    At the end of February we announced the arrival of the first US recession since 2009 and we predicted that the market will decline by at least 20% in (Recession is Imminent: We Need A Travel Ban NOW). In these volatile markets we scrutinize hedge fund filings to get a reading on which direction each […]

  • TheStreet.com

    Microcap Akers Biosciences Spikes on Covid-Vaccine Progress

    Akers and Premas Biotech are three steps into a four-step plan that could lead to clinical trials of a vaccine candidate.

  • Akers Biosciences plans $4.6M stock sale, advances COVID-19 vaccine candidate
    American City Business Journals

    Akers Biosciences plans $4.6M stock sale, advances COVID-19 vaccine candidate

    Akers Biosciences Inc., a South Jersey medical device company that recently joined the race to develop a COVID-19 vaccine, plans to raise $4.6 million in a public stock sale. The Thorofare-based company is selling 766,667 shares of its common stock at a purchase price of $6.00 per share, according to documents filed with the Securities and Exchange Commission. Last month, Akers entered into an in-licensing and product development deal for a coronavirus vaccine candidate under development by Premas Biotech.

  • Akers Says It's Halfway Through Plan To Develop COVID-19 Vaccine Candidate
    Benzinga

    Akers Says It's Halfway Through Plan To Develop COVID-19 Vaccine Candidate

    Akers Biosciences Inc (NASDAQ: AKER), which said earlier this week that it is one step closer to identifying a coronavirus vaccine candidate, announced another successful milestone Wednesday in its vaccine development program.The New Jersey-based company said that it, along with developmental partner Premas Biotech, has successfully completed the second milestone of successful expression of the three coronavirus antigens -- spike, envelop and membrane --selected for their vaccine candidate.Benzinga is covering every angle of how the coronavirus affects the financial world. For daily updates, sign up for our coronavirus newsletter."The antigens have been expressed using the D-CryptTM platform at Premas Biotech, which utilizes its vectors and S cerevisiae strain," according to Akers. Premas will now move ahead with purification and post-expression processing that will lead to a scaling up of the antigen, according to a press release. The company is now halfway through a four-milestone plan that it believes will lead to the commencement of clinical trials, Akers Executive Chairman Christopher Schreiber said in a statement. Akers shares were advancing 6.14% to $6.05 at the time of publication Wednesday. Related Links:Analyst Projects Over 130% Upside In This Biopharma Teva Analyst Says Shares Are Pricing In Too Much Risk See more from Benzinga * The Daily Biotech Pulse: Mesoblast To Test Candidate On Coronavirus Symptoms, Proxy Battle Ahead For Rockwell Medical, Glaukos to Join S&P SmallCap 600 Index * The Daily Biotech Pulse: Sangamo In Genome-Editing Therapy Deal With Biogen, FDA Nod For Biohaven, Passage Bio IPO(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

  • South Jersey company's stock closes up 22% after coronavirus vaccine deal
    American City Business Journals

    South Jersey company's stock closes up 22% after coronavirus vaccine deal

    The point-of-care test kit company has in-licensed an experimental vaccine under development for the coronavirus.

  • Benzinga

    The Daily Biotech Pulse: Cassava Gains On Alzheimer's Presentation, Bristol-Myers Hikes Dividend

    Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks hitting 52-week highs on Dec. 5) ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD )(presented ...

  • South Jersey medical device maker raising $8M through stock offering
    American City Business Journals

    South Jersey medical device maker raising $8M through stock offering

    The company, which develops and markets point-of-care diagnostic products, is continuing to evaluate 'strategic business alternatives.'